A detailed history of Cormorant Asset Management, LP transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 3,406,534 shares of EWTX stock, worth $102 Million. This represents 6.37% of its overall portfolio holdings.

Number of Shares
3,406,534
Previous 3,006,534 13.3%
Holding current value
$102 Million
Previous $54.1 Million 67.91%
% of portfolio
6.37%
Previous 4.17%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.88 - $29.5 $6.35 Million - $11.8 Million
400,000 Added 13.3%
3,406,534 $90.9 Million
Q1 2024

May 15, 2024

BUY
$9.25 - $19.97 $4.2 Million - $9.08 Million
454,545 Added 17.81%
3,006,534 $54.8 Million
Q4 2023

Feb 14, 2024

SELL
$5.51 - $12.1 $2.18 Million - $4.78 Million
-394,898 Reduced 13.4%
2,551,989 $27.9 Million
Q4 2022

Feb 14, 2023

SELL
$7.58 - $11.08 $796,673 - $1.16 Million
-105,102 Reduced 3.44%
2,946,887 $26.3 Million
Q3 2022

Nov 14, 2022

SELL
$8.08 - $13.58 $6.45 Million - $10.8 Million
-798,011 Reduced 20.73%
3,051,989 $30 Million
Q2 2022

Aug 15, 2022

SELL
$5.67 - $9.87 $4.72 Million - $8.22 Million
-832,874 Reduced 17.79%
3,850,000 $30.6 Million
Q1 2022

May 16, 2022

BUY
$9.1 - $18.97 $10.2 Million - $21.2 Million
1,116,973 Added 31.32%
4,682,874 $45.4 Million
Q4 2021

Feb 14, 2022

BUY
$14.41 - $22.41 $2.81 Million - $4.37 Million
194,987 Added 5.78%
3,565,901 $54.5 Million
Q3 2021

Nov 15, 2021

BUY
$14.11 - $24.1 $3.25 Million - $5.54 Million
230,000 Added 7.32%
3,370,914 $56 Million
Q2 2021

Aug 16, 2021

BUY
$21.33 - $30.25 $17.1 Million - $24.2 Million
800,000 Added 34.17%
3,140,914 $66.5 Million
Q1 2021

May 17, 2021

BUY
$30.0 - $35.99 $70.2 Million - $84.2 Million
2,340,914 New
2,340,914 $74.3 Million

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.89B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.